Chronic Hepatitis B Virus (CHB) Market
DelveInsightu2019s u2018Chronic Hepatitis B Virus (CHB) - Market Insights, Epidemiology and Market Forecast u20142030u2019 report delivers an in-depth understanding of the CHB, historical and forecasted epidemiology as well as the CHB market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, and use of illegal drugs, unsterilized or contaminated needles. HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a u201csilent epidemicu201d because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1u20132 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%). The CHB market report provides current treatment practices, emerging drugs, CHB market share of the individual therapies, current and forecasted CHB market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CHB treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
96 views • 6 slides
